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Prognostic factors in adult Non-Hodgkin’s lymphoma patients
Edyta Jab∏oƒska
P u r p o s e. Over the past 30 years the incidence of the Non-Hodgkin’s lymphoma (NHL) in Europe and in the United Sta-
tes has increased dramatically. The Polish NHL patients have yet significantly poorer survival as compared with the NHL pa-
tients in the E.U. countries.
The aim of this study was to define prognostic factors determining the prognosis of NHL patients. This could help to select
a group of patients who require more intensive treatment.
Pa t i e n t s  a n d  m e t h o d s. I reviewed and reclassified 174 cases of NHL patients treated in the Oncology Clinic of the Ja-
giellonian University in Krakow in 1971-1999. I estimated some social-economic features of the patients as well as the diagno-
stic and clinical features of the disease.
R e s u l t s . Univariate analysis showed that there were two groups of factors influencing survival: lack of the abdominal
computer tomography examination and certain clinical features of the disease. Therefore I decided to search for prognostic fac-
tors among the patients who were properly diagnosed, e.g. who underwent the abdominal computer tomography examination.
Multivariate analysis in the group of patients with indolent NHL showed that there were two factors decreasing the overall su-
rvival (OS): diffused localisation of the disease and the elevated level of LDH. For disease-free survival (DFS) there was one
independent prognostic factor, e.g. the value of International Prognostic Index (IPI). In patients with aggressive NHL the va-
lue of IPI significantly influenced the OS and the DFS. In this group I discovered also that anemia decreases the OS. In pa-
tients with high-aggressive NHL the independent prognostic for the OS was clinical stage IV and for the DFS the elevated le-
vel of LDH. Retrospective analysis revealed that the achievement of the CR substantially improves the OS. Common featu-
res that make difficult to achieve the CR in all lymphoma group were: bulky disease with the tumour size over 10 cm, low
performance status (>1 according the WHO) and anemia.
C o n c l u s i o n. In summary, my analysis indicates that the improvement of the outcome among the Polish NHL patients is
associated with the improvement of the diagnosis. In addition, the high-risk NHL patients according the IPI should be
considered as candidates for more intensive treatment. In the high-risk group of indolent NHL patients, chemotherapy
combined with immunotherapy is recommended. In the high-risk group of aggressive NHL patients earlier qualification for
myeloablative chemotherapy with subsequent PBSCT should be suggested.
Czynniki rokownicze u chorych doros∏ych na ch∏oniaki nieziarnicze
Cel. W ciàgu ostatnich trzydziestu lat w ca∏ej Europie i Ameryce Pó∏nocnej obserwuje si´ wyraêny wzrost zachorowalnoÊci na
ch∏oniaki nieziarnicze. W populacji polskiej zwracajà uwag´ znamiennie gorsze 5-letnie prze˝ycia w porównaniu z krajami Unii
Europejskiej. Wzrost ryzyka zachorowania na ch∏oniaki nieziarnicze wià˝e si´ prawdopodobnie ze zwi´kszeniem ekspozycji na
czynniki rakotwórcze, zaka˝eniami wirusami (HIV, HTLV-1, Epstein-Barr), poprawà diagnostyki i zmianami w klasyfikacji.
Obecnie utworzona nowa klasyfikacja REAL zak∏ada, ˝e ch∏oniaki nieziarnicze stanowià heterogennà grup´ nowotworów,
z których ka˝dy jest odr´bnà jednostkà chorobowà, definiowanà przez okreÊlone cechy kliniczne, histopatologiczne, immuno-
logiczne i genetyczne. W praktyce jednak najbardziej u˝yteczny z klinicznego punktu widzenia pozostaje nadal podzia∏ na trzy
grupy: o niskiej, wysokiej i najwy˝szej z∏oÊliwoÊci. Podzia∏ ten uwzgl´dnia „sformu∏owanie robocze”, które sta∏o si´ podstawà
przeklasyfikowania wszystkich postaci morfologicznych analizowanych ch∏oniaków.
M a t e r i a ∏  i m e t o d y. Weryfikacji histopatologicznej poddano 174 chorych leczonych w Klinice Onkologii CMUJ w latach
1971–1999. Za∏o˝eniem niniejszej analizy by∏a próba ustalenia przed rozpocz´ciem leczeniem niezale˝nych czynników pogar-
szajàcych rokowanie, a tym samym mo˝liwoÊç wyselekcjonowania grupy chorych wymagajàcych bardziej intensywnego lecze-
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Introduction
In Poland 1747 were observed newly diagnosed cases of
non-Hodgkin’s lymphoma (1.6% of all malignant neo-
plasms), and 1148 deaths (1.4% of all deaths) in 1996
[1]. In 1990 in non-Hodgkin’s lymphomas made up abo-
ut 3% of all malignant neoplasms and 3.5% of all de-
aths the European Union [2]. These data suggest that
the proportion of non-Hodgkin’s lymphomas to all mali-
gnant neoplasms is lower in Poland than in Western co-
untries. Since 1960 almost everywhere in Europe, espe-
cially in Scandinavian countries and the European Union
the incidence of non-Hodgkin’s lymphoma has been ri-
sing by 15-40% every 5 years [3]. In Poland mortality
due to NHL in men has been rising since mid 60s. The
risk of death in Poland increased in men by 1.5-fold and
in women by 1.6-fold from 1965 to 1995. Both in women
and men born in the 60s the risk of death due to NHL
was 10 times higher than in those born at the end of the
20th century [3]. In Krakow the risk of NHL increased
between 1983 and 1992 in men by 23% whereas in wo-
men it remained unchanged [4, 5]. In contrast to Hodg-
kin’s disease the therapeutic outcome is much lower and
mortality due to NHL has not decreased. In Europe an
average relative 5-year survival of patients with Hodg-
kin`s disease was 72% in 1985-1989, but in those with
NHL it was c. 45%.The relative survival in the Polish
population of patients with Hodgkin’s disease does not
differ significantly from that in Europe. In case of NHL
the relative 5-year survival in Polish patients was only
32% i.e. by 14% lower than the European average, the
difference being significant [6]. These facts i.e. the ri-
sing risk of NHL in the Polish population and signifi-
cantly worse 5-year survival as compared with the Euro-
pean Union prompted me to undertake a search for fac-
tors significantly affecting prognosis in patients with these
malignancies. In consequence this should facilitate ade-
quate treatment and improve survival of Polish patients
with NHL. The identification of the prognostic factors si-
gnificantly affecting the prognosis in the Polish popula-
tion is the main objective of the present study. Three
main types of NHL are analysed: low grade, intermedia-
te grade and high grade lymphomas.
Material and methods
Between 1971 and 1999 were admitted to 174 patients with NHL
in whom the diagnosis was confirmed by histopathology the De-
partment of Oncology Jagiellonian University Medical Colle-
ge. In all patients we revised the morphological diagnosis of
NHL. For the purposes of the present analysis NHL was divided
into three main groups: low grade, intermediate grade and high-
-grade lymphomas. Using clinical documentation of the patients
their age, sex, residence, marital status, occupation and smo-
king status were established.
The following diagnostic procedure were also taken into
account:
a) lactate dehydrogenase level (according to the Laboratory of
Diagnostics of the Jagiellonian University Medical College
150–460 U/L),
b) imaging studies: ultrasound of the abdomen, computerised
tomography of the abdomen, bilateral limb lymphography
and liver scintigraphy,
c) microscopy studies of the bone marrow (biopsy and myelo-
gram).
nia. Ka˝dego chorego oceniono pod wzgl´dem cech spo∏eczno-ekonomicznych, przeÊledzono przeprowadzone badania dia-
gnostyczne oraz uwzgl´dniono charakterystyk´ klinicznà choroby.
W y n i k i . Analiza jednocechowa wykaza∏a, ˝e istotne dla prze˝yç sà dwie odr´bne grupy czynników, tj. brak badania tomo-
grafii komputerowej jamy brzusznej oraz niektóre cechy kliniczne choroby. Stàd te˝ postanowiono dodatkowo przeprowadziç
poszukiwanie niezale˝nych czynników rokowniczych dla chorych prawid∏owo zdiagnozowanych, tj. tych, u których wykona-
no badanie KT jamy brzusznej, zak∏adajàc, ˝e u takich chorych prawid∏owo oceniono zasi´g choroby. Cechy, które okaza∏y si´
istotne w analizie jednocechowej, wprowadzono nast´pnie do modelu wielocechowego Coxa w poszukiwaniu niezale˝nych
czynników rokowniczych. Analiza wielocechowa w grupie chorych o niskiej z∏oÊliwoÊci wykaza∏a, ˝e cechami istotnie pogar-
szajàcymi prze˝ycia ca∏kowite by∏y: obecnoÊç lokalizacji rozlanej i podwy˝szony poziom LDH. Dla prze˝yç bezobjawowych na-
tomiast istotne znaczenie rokownicze ma wartoÊç mi´dzynarodowego wskaênika rokowniczego ponad 1. W grupie chorych
z ch∏oniakami o wysokiej z∏oÊliwoÊci istotnie pogarszajàca prze˝ycie ca∏kowite i bezobjawowe okaza∏a si´ wartoÊç mi´dzyna-
rodowego wskaênika rokowniczego ponad 1. Wykazano ponadto, ˝e istotne znaczenie rokownicze dla prze˝yç ca∏kowitych w tej
grupie chorych ma niedokrwistoÊç. W grupie chorych z ch∏oniakami o najwy˝szej z∏oÊliwoÊci niezale˝nym czynnikiem rokow-
niczym dla prze˝yç ca∏kowitych by∏ IV stopieƒ zaawansowania klinicznego choroby, a dla prze˝yç bezobjawowych podwy˝szo-
ny poziom dehydrogenazy mleczanowej. W retrospektywnej ocenie wyników i odpowiedzi na leczenie okaza∏o si´, ˝e uzyska-
nie najlepszej odpowiedzi na leczenie, tj. uzyskanie ca∏kowitej remisj, poprawia istotnie prze˝ycia chorych. Wspólnà cechà utrud-
niajàcà uzyskanie ca∏kowitej remisji jest masywnoÊç zmiany z wymiarem ponad 10 cm oraz obni˝ony stan ogólnej sprawnoÊci
(wed∏ug WHO≥2).
W n i o s k i. Na podstawie przeprowadzonej analizy stwierdzono, ˝e poprawa prze˝yç chorych z ch∏oniakami nieziarniczymi wià-
˝e si´ z poprawà diagnostyki, jak i rozwa˝eniem indywidualnie bardziej intensywnego leczenia u chorych z grup podwy˝szone-
go ryzyka zgonu i nawrotu choroby, obarczonych przede wszystkim wartoÊcià mi´dzynarodowego wskaênika rokowniczego po-
nad 1. U takich chorych z ch∏oniakami o niskiej z∏oÊliwoÊci nale˝a∏oby rozwa˝yç wczeÊniejszà kwalifikacj´ do chemio-immu-
noterapii, a u chorych z ch∏oniakami o wysokiej z∏oÊliwoÊci do chemioterapii mieloablacyjnej z autologicznym przeszczepieniem
komórek macierzystych.
Key words: prognostic factors, NHL, IPI
S∏owa kluczowe: czynniki prognostyczne, ch∏oniaki, IPI
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The following clinical characteristics were analysed: pre-
sence of generalised symptoms (B) or their absence (A) [7–9],
performance status according to the WHO (scale from 0 to 4),
bulk of the lesion i.e. dimension of the largest palpable mass of
the lymphoma in centimetres (physically or by imaging), bone
marrow and spleen involvement, location (nodal, extranodal,
diffuse), clinical stage (according to the Ann Arbor system,
1971) and the International Prognostic Index (IPI). For all pa-
tients the International Prognostic Index was calculated based
upon the presence or absence of the following high risk fac-
tors [16–19]:
a) age over 60,
b) stage according to the Ann Arbor system > II
c) more than one extranodal site,
d) limited performance (according to the WHO ≥2),
e) serum lactate dehydrogenase > normal level.
Depending on the number of high-risk factors the pa-
tients were divided into four groups at risk. For each group
overall and disease free 5-year survival was calculated. Additio-
nally the age-adjusted international prognostic index was calcu-
lated based upon the presence or absence of the following high-
-risk factors:
a) stage according to the Ann Arbor system > II,
b) serum lactate dehydrogenase > normal level,
c) limited performance (according to the WHO ≥2).
The calculations were done separately for the patients
aged 60 and younger and for the patients over 60. This dichoto-
my was used because survival of patients over 60 years of age is
usually worse than in younger patients [20-26]. For each risk
group overall and symptom free 5-year survival was establi-
shed.
Treatment modalities taken into account were chemothera-
py, radiotherapy, surgical and combined treatment. A group of
untreated patients was identified. The methods of combined
treatment were characterised. The effect of splenectomy on the
outcome was established. I also identified the number and pro-
portion of patients who received chemotherapy containing anth-
racyclines or not, as well as required and decreased chemothera-
py dose.
S t a t i s t i c a l  a n a l y s i s
Prognostic factors were analysed using standard procedures.
All potential prognostic factors were either by nature qualitati-
ve (e.g. sex) or were categorised according to the generally ac-
cepted cut-off points (e.g. norm in case of LDH). Overall and
symptom free survival curves were estimated according to Ka-
plan-Meier, including truncated data points [27]. Survival was
compared using log-rank tests [28]. Tables summarise 5-year
survival and p values. In certain categories of features survival
did not exceed 5 years, but a certain number of patients is still
under observation. The last observed survival is marked in pa-
rentheses, which means that 5-year survival cannot be higher
than that. The most important results were plotted to obtain su-
rvival curves. In all statistical tests used in the study a diffe-
rence was deemed significant when the value of the associated
test probability (p value) was lower than the level of signifi-
cance α = 0.05. Base upon the results of log-rank test a set of
initial significant prognostic factors was identified. Complete da-
ta were obtained using multidimensional Cox models. A preli-
minary set of explanatory variables in these models were factors
with variability found in univariate analysis (i.e. log-rank test).
Then a step-wise regression procedure in the descending mode
was used removing from the model step by step those varia-
bles which in a given estimating process had the highest (and hi-
gher than 0.05) p value. The process of variable removal was
completed when all relative risks were statistically significant.
This model permits identification of independent prognostic
factors, their mutual standardisation and comparison of power
[29]. Tables summarise the relative risk with the 95% confiden-
ce interval and p value associated with this risk. In some univa-
riate analyses because of a small number of nontruncated obse-
rvations (that is terminated by relapse or death) it was not possi-
ble to estimate survival or Cox models. These data are mar-
ked with a dot in the table. In analyses of relationships between
qualitative and categorised variables (e.g. the presence of ana-
emia and severity) chi square test of independence was used
[30].
Results – impact on survival
Low grade lymphomas
In analysis of overall survival in all patients with low
grade NHL the following variables significantly affec-
ting overall survival in univariate analysis were used in
the preliminary model: age over 60, no CT scan of the
abdomen, diffuse location, anaemia, elevated LDH, sta-
ge IV disease and IPI over 1, assuming that the index
may be the most significant prognostic factor. None of
the above mentioned characteristics was a significant
prognostic factor affecting overall survival. In analysis of
symptom free survival in patients with low grade NHL
the preliminary model included the following variables
which appeared significant in univariate analysis: presen-
ce of B symptoms, diffuse location, bulk over 10 cm,
anaemia, elevated LDH and IPI over 1. Using step-wise
regression in the multivariate model no independent
characteristic was found to significantly affect symptom
free survival. A separate multivariate analysis of ove-
rall survival was carried out for patients who underwent
abdominal computerised tomography introducing in the
initial stage the factors which were significant in univa-
riate analysis: age over 60, stage IV disease, anaemia,
elevated LDH, involvement of the bone marrow, diffuse
location and IPI over 1. In the final model one signifi-
cant prognostic factor was identified for this group of pa-
tients i.e. elevated LDH. The results are summarised in
the Table I.
Tab. I. The effect of prognostic factors on overall 5-year survival 
in patients with low grade non Hodgkin’s lymphomas 
who underwent computerised tomography of the abdomen
Characteristic Relative risk of death p Confidence interval
LDL level
Normal 1.00
> normal 6.47 0.0002 2.41 – 17.35
Multivariate analysis of symptom free survival in this
group of patients included the following factors which
appeared significant in univariate analysis: presence of
generalised B symptoms, diffuse location, bulk over 10
cm, anaemia, elevated LDH and IPI over 1. The final
analysis revealed one prognostic factor significant for
symptom free survival i.e. international prognostic index
IPI over 1 (see Tab. II).
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Tab. II. The effect of prognostic factors on symptom free 5-year survi-
val in patients with low grade non-Hodgkin’s lymphomas who under-
went computerised tomography of the abdomen
Characteristic Relative risk of relapse p Confidence interval
IPI
IPI≤ 1.00
IPI>1 2.42 0.0131 1.20 – 4.90
I n t e r m e d i a t e  g r a d e  l y m p h o m a s
Analysis of overall survival in all patients with intermedia-
te grade non-Hodgkin’s lymphomas included in the initial
model the following variables which appeared significant
in univariate analysis: age over 60, no CT scan of the ab-
domen, anaemia, stage IV disease, performance status
according to the WHO ≥2, elevated serum LDH and IPI
over 1 assuming that similar to low-grade lymphomas IPI
may be the most significant prognostic factor. In the final
step the proportional hazard model revealed three inde-
pendent prognostic factors: no CT scan of the abdomen,
anaemia and IPI over 1.
Tab. III. The effect of prognostic factors on overall 5-year survival
in patients with intermediate grade non-Hodgkin’s lymphomas
(all patients)
Characteristic Relative risk of death p Confidence interval
CT of 
the abdomen
Yes 8.43 0.0003 2.66 – 26.74
No 1.00
Anaemia
Yes 3.31 0.0214 1.19 – 9.18
No 1.00
IPI
IPI1≤1 1.00
IPI>1 6.45 0.0010 2.13 –19.49
When analysing symptom free survival of patients
with intermediate-grade NHL the following variables
which appeared significant in univariate analysis were ta-
ken into account: no CT scan of the abdomen, stage IV
disease, anaemia, elevated LDH and IPI >1. In the final
step multivariate analysis of 5-year symptom free survival
revealed two independent prognostic factors i.e. no CT
scan of the abdomen and IPI >1 (see Table IV).
An additional multivariate analysis of survival was
carried out in patients who underwent abdominal CT
scanning. Analysis of overall survival included in the initial
stage factors which were significant in univariate analysis:
age over 60, performance status according to the WHO
≥2, stage IV disease, anaemia, elevated LDH and IPI
>1.
The final model revealed two independent progno-
stic factors in this group of patients i.e. anaemia and IPI
>1 (see Table V).
Tab. V. The effect of prognostic factors on overall 5-year survival
in patients with high grade non Hodgkin’s lymphomas
who underwent abdominal computerised tomography
Characteristic Relative risk of death p Confidence interval
Anaemia
Yes 4,19 0,01339 1,35 – 13,04
No 1,00
IPI
0, 1 1,00
> 1 4,72 0,00965 1,46 – 15,32
Analysis of symptom free survival in this group of
patients included the following features significantly affec-
ting survival in univariate analysis: stage IV disease, ana-
emia, elevated LDH and IPI >1. In the final version ana-
lysis of symptom free survival revealed one independent
prognostic factor i.e. IPI >1 (see Table VI).
Tab. VI. The effect of prognostic factors on symptom free 5-year
survival in patients with high grade non Hodgkin’s lymphomas
who underwent abdominal computerised tomography
Characteristic Relative risk of relapse p Confidence interval
IPI
0.1 1.00
>1 6.07 0.0056 1.69-21.75
H i g h  g r a d e  l y m p h o m a s
Analysis of high grade lymphomas was carried out separa-
tely because this group included lymphoblastic and Bur-
kitt’s lymphomas. These variants are characterised by ra-
pid growth, and their detection is an indication for imme-
diate treatment without completing the diagnostic
procedure. The results of analysis in this group of pa-
tients, because of its small size were regarded as approxi-
mate. In the final version multivariate analysis of overall
5-year survival revealed one independent prognostic fac-
tor: stage IV disease. Analysing the effect of prognostic
factors on symptom free survival of patients with high
grade non Hodgkin’s lymphomas only elevated LDH was
taken into consideration as the only statistically significant
variable in univariate analysis. For this reason it was not
possible to establish a multivariate model.
Tab. IV. The effect of prognostic factors
of symptom free 5-year survival in patients with high-grade
non Hodgkin’s lymphomas (all patients)
Characteristic Relative risk of relapse p Confidence interval
CT of 
the abdomen
Yes 3.36 0.0161 1.25 – 9.04
No 1.00
IPI
0.1 1.00
>1 4.81 0.0015 1.83 – 12.68
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Discussion
From the clinical point of view it is still most useful to
divide non-Hodgkin’s lymphomas into low grade, interme-
diate grade and high grade (aggressive) lymphomas [11,
12, 31]. This division best reflects “working formulation”
and it served as the basis of revised classifications of all
morphological forms of non-Hodgkin’s lymphomas tre-
ated in the Department of Oncology Jagiellonian Uni-
versity Medical College between 1972 and 1999. Available
data indicate that it is not a selected material and clinical-
ly resembling to the material of the Centre of Oncology
Ward in Krakow [32] (see Table VII).
Tab. VII. Clinical characteristics of patients with non-Hodgkin’s
lymphomas treated in the Centre of Oncology in Krakow (COOK)
between 1978 and 1986 and in the Department of Oncology
Jagiellonian University Medical College (KO) between 1972 and 1999
Characteristic Low grade High grade
COOK KO COOK KO
(n=156) (n=87) (n=97) (n=87)
Sex
Men 99 (63.5%) 54 (58.6%) 53 (54.6%) 49 (56.3%)
Women 57 (36.5%) 33 (37.9%) 44 (45.4%) 38 (43.7%)
Staging
I 30 (19.2%) 12 (13.8%) 12 (12.4%) 10 (11.9%)
II 22 (14.5%) 16 (18.3%) 25 (25.8%) 32 (36.7%)
III 32 (20.5%) 29 (33.3%) 22 (22.6%) 18 (20.6%)
IV 72 (46.2%) 30 (34.5%) 38 (39.2%) 24 (28.6%)
Symptoms
A 112 (71.8%) 57 (65.5%) 63 (64.9%) 57 (65.5%)
B 44 (28.2% 30 (34.5%) 34 (35.1%) 30 (34.5%)
There were no statistically significant differences in
the clinical characteristics between the Centre of Oncolo-
gy and the Department of Oncology. For this reason it is
highly probable that the analysed material is represen-
tative for the patients treated in specialised institutions in
Krakow. The therapeutic outcome reflecting 5-year survi-
val achieved in both institutions is summarised in Table
VIII. Additionally it was compared with survival of pa-
tients in other institutions [17].
Tab. VIII. Five-year survival in patients with non Hodgkin’s
lymphomas obtained in the Centre of Oncology in Krakow (COOK)
and the Department of Oncology Jagiellonian University
Medical College (KO)
Centre 5-year survival
Low grade High grade
COOK (1978-1986) [33] 39.1% (35.2 – 43.0) 22.7% (14.4 – 31.0)
KO (1971-99) 47.8% (37.3 – 58.3) 31.8% (21.3 – 42.3)
Other institutions [34] 68.2% (59.2 – 77.2) 52.0% (49.8 – 54.2)
The data in this table suggest that the therapeutic
outcome in both centres in Krakow is not significantly
different. However, it is significantly worse than in other
countries. In order to improve these results it seems justi-
fied to find out significant adverse prognostic factors
that would permit identification of patients requiring
more aggressive treatment. This will enable us to tailor
therapy to the individual patients identifying a subgroup
of patients who would benefit from intensive treatment
and avoiding too aggressive treatment in patients witho-
ut adverse prognostic factors. Initial univariate analysis
revealed that the following characteristics had a statisti-
cally significant effect on overall survival in patients with
low grade NHL: age over 60, no abdominal CT scan,
diffuse location, bone marrow involvement, stage IV di-
sease, anaemia, elevated LDH and IPI over 1. For symp-
tom free survival the significant features were as follows:
presence of B symptoms, diffuse location, bulk over 10
cm, anaemia, elevated LDH and IPI over 1. In patients
with intermediate grade NHL log rank test revealed that
overall survival was affected by age over 60, no abdomi-
nal CT scan, stage IV disease, performance status ac-
cording to the WHO ≥2, anaemia, elevated LDH and
IPI over 1. The characteristics affecting symptom free
survival in this group of patients were no abdominal CT
scan, stage IV disease, anaemia, elevated LDH and IPI
over 1. Finally in patients with high grade NHL univaria-
te analysis revealed that overall survival was influenced
significantly by stage of the disease (I+II+III versus
IV), and whereas symptom free survival was affected by
LDH level.
Failure to perform abdominal computerised tomo-
graphy has a significant adverse effect on the prognosis
both in patients with low grade (overall survival) and in
patients with high grade NHL (overall and symptom free
survival). Computerised tomography of the abdomen is
a stage-of-the-art technique most useful in evaluating the
lymph nodes below the diaphragm and abdominal organs
[35]. For this reason no CT scan of the abdomen is equ-
ivalent to imprecise staging of NHL. This in turn results in
the fact that the patients frequently do not receive treat-
ment, which is adequate to the disease extent. Figures 1
and 2 display survival curves in patients with NHL de-
pending on whether CT scan of the abdomen was obta-
ined or not.
These figures show that the lack of CT data is a si-
gnificant factor adversely affecting overall survival. For
this reason it was decided to regard as most significant
those prognostic factors which were significant in fully
diagnosed patients i.e. with CT scan of the abdomen. In
patients with low grade NHL elevated LDH was an inde-
pendent prognostic factor significantly aggravating ove-
rall survival, and in patients with IPI over 1 symptom
free survival was significantly decreased. In other words,
in patients with low grade NHL the presence of more
than one characteristic referred to as the international
prognostic index precipitates relapse. The International
Prognostic Index (IPI) was primarily established and its
usefulness for survival was confirmed in patients with
high grade lymphomas [10, 16, 19, 36, 37]. Based upon
this index we identify four groups at risk corresponding to
the number of risk factors. It has been demonstrated
that patient survival both overall and symptom free de-
creases with the increasing number of risk factors. For
patients up to 60 years of age and for patients over 60
years an additional simplified model was defined the so-
-called age-adjusted prognostic index. This model is used
in experimental clinical trials in younger patients i.e. up
to 60 years of age [19]. So far it has not been clear whe-
ther in low-grade lymphomas the same features which
are included in the international prognostic index are
significant. According to some investigators such features
as extranodal sites, age over 60, stage IV disease and
elevated LDH are associated with adverse prognosis in
patients with low grade NHL [17, 38, 39]. Other investi-
gators made an attempt to establish a predictive model
based upon the presence of the following features: bulk
over 5 cm, number of extranodal sites >1, male sex and
extent of bone marrow involvement over 20%. These fe-
atures were independent prognostic factors of relapse
and their presence had an adverse effect on survival [40].
In recent reports a significant factor adversely affecting
overall survival was age over 60, B symptoms and at least
three nodal sites each larger than 3 cm [41]. The pre-
sent study has demonstrated that also for patients with
low grade NHL in whom CT scan of the abdomen was
obtained it is important to establish before treatment.
It appeared the only independent prognostic factor affec-
ting symptom free survival. As Table II shows IPI score
>1 is associated with a two-fold increase of risk for relap-
se. According to recent reports the IPI also significantly
affects overall survival, especially in patients with more
than three risk factors [18, 38, 42]. In patients with inter-
mediate grade lymphomas in whom CT of the abdomen
was performed multivariate analysis revealed that the
presence of such characteristics as anaemia and IPI sco-
re >1 significantly decreases overall survival. As for
symptom free survival only IPI score >1 is the most signi-
ficant prognostic factor. The Table IX summarises the
effect of the IPI on survival in patients with low- and
high-grade non-Hodgkin’s lymphomas.
As the table shows IPI score >1 has a significant ef-
fect on survival in patients with complete diagnosis. In
patients with high grade non-Hodgkin’s lymphomas it si-
gnificantly increases the risk of death and relapse. In pa-
tients with low-grade lymphomas IPI score >1 is asso-
ciated with a significantly increased risk of relapse, but it
does not significantly affect overall survival.
The present study shows that the IPI calculated prior
to treatment helps us to estimate the percent of comple-
te remission and survival indicating a significant deterio-
ration of therapeutic outcome with the increasing IPI.
Thus, to the best of our knowledge the information abo-
ut IP appears to be most important when deciding about
treatment for patients with low- and intermediate-grade
non-Hodgkin’s lymphomas [17, 18, 38, 41, 43, 44].
In patients with high-grade lymphomas stage IV di-
sease was the only, independent prognostic factor influen-
cing overall survival. Symptom free survival in this subgro-
up deteriorated significantly with increasing LDH. Be-
cause of a small size of the group it was not possible to
search for the prognostic factors in patients who under-
went CT of the abdomen.
From the viewpoint of cure it is most important to
achieve symptom free survival. Complete remission is
a fundamental indicator of symptom free survival [45].
The present study shows that complete remission is a sta-
tistically significant characteristic affecting patient survi-
val. However, complete remission is a characteristic,
which cannot be predicted before treatment. For this re-
ason, multivariate models to analyse the prognostic fac-
tors, which are important before the onset of treatment
did not include this characteristic. However, chi-square
test of independence revealed a relationship between
complete remission and other characteristics.
Fig. 1. Overall survival in patients with low grade non-Hodgkin’s lympho-
mas depending on whether abdominal CT examination was obtained or not
Fig. 2. Overall survival in patients with high grade NHL depending on
whether abdominal CT examination was obtained or not
Tab. IX. The effect of the IPI on overall and disease-free survival
in patients with low- and high-grade non-Hodgkin’s lymphomas
in whom CT scan of the abdomen was obtained
overall survival disease-free survival
Grade IPI relative risk p value relative risk p value
of death of relapse p
Low 0.1 1.00 0.4232 1.00 0.0131
>1 2.07 2.42
High 0.1 1.00 0.01339 1.00 0.0056
>1 4.72 6.07
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The clinical characteristics, which negatively affected
complete remission in patients with low- and interme-
diate grade lymphomas were as follows: bulk over 10 cm,
anaemia and limited performance according to the
WHO ≥2. Thus, improvement of therapeutic outcome
depends on improved diagnostic process in its broad sen-
se. Another important step is appropriate treatment ad-
ministered to patients with IPI >1, both in low- and inter-
mediate grade lymphomas. Patients with low-grade lym-
phomas can be managed in different ways. In
asymptomatic patients at first diagnosis it seems most
appropriate to take a wait-and-see approach [40, 46, 47,
48]. Treatment in these patients is usually initiated when
they develop subjective and secondary symptoms of pro-
gression [49]. This approach is based on the assumption
that the chances of cure are very small. The natural cour-
se of the disease is slow (for this reason they are referred
to as indolent lymphomas), with frequent relapses ma-
nifest as clinical progression [50]. That is why treatment is
administered not to cure but to stabilise the disease pro-
cess using minimal toxic modalities. This is reflected in the
present findings in patients with low-grade lymphomas
in whom symptom free survival is even poorer than in
patients with intermediate grade lymphomas. However, it
seems that in patients with low-grade non-Hodgkin’s lym-
phomas and IPI score >1 treatment should be more ag-
gressive. In patients with increased risk of death and re-
lapse in whom it is possible to estimate a probability of re-
mission and survival initiation of intensive treatment
should be considered. Chemotherapy drugs should inclu-
de alkylating agents (cyclophosphamide, chlorambucil),
steroids and purine analogues (Fludarabine, Cladribine)
as first choice drugs [51]. Especially purine analogues are
promising, because they affect inactive lymphocytes in
the cellular cycle, which are predominant in patients with
low-grade lymphomas. Interferon alpha-2 has also been
found to prolong the duration of remission after chemo-
therapy [10, 52]. The combination of chemotherapy and
immunotherapy (Rituximab, Campath) with radioimmu-
notherapy seems also effective [53-56]. In younger pa-
tients high-dose chemotherapy with subsequent stem cell
transplantation should also be considered [57-59]. This hi-
ghly toxic approach prolongs the duration of remission in
70% of patients [58-59]. The effect of these monoclonal
antibodies on long-term survival has yet to be evaluated.
Such treatments cannot be offered to all patients. They
should be considered in those patients in whom IPI score
exceeds 1. At present the CHOP + Mabthera regimen
can be effective (cyclophosphamide 750 mg/m2 on day 1
+ doxorubicin 50 mg/m2 on day 1 + vincristine 1.4 mg/m2
on day 1, prednisone 100 mg/m2 orally on days 1to 5 eve-
ry 3 weeks combined with Mabthera 375 mg/m2 every 2-4
weeks) [53, 56].
In patients with intermediate grade lymphomas tre-
atment is initiated to achieve complete remission. Only
this approach is associated with cure and even long-term
survival in about 35% of patients. The most frequent
cause of failure in this subgroup is the dynamics of the di-
sease leading sometimes to refractoriness as well as
expansiveness at critical sites (mediastinum, central ne-
rvous system, and abdomen). For this reason chances of
cure increase with aggressiveness of chemotherapy. Re-
cent studies have demonstrated that the duration of re-
mission and LDH at relapse significantly affect long-
-term survival. In patients with the disease relapsing wi-
thin a period shorter than 12 months as well as in
patients who did not respond to initial conventional che-
motherapy one should consider intensified chemothera-
py with subsequent peripheral blood stem cell transplan-
tation [36, 60, 61, 62, 63]. To the best of our knowledge
the most appropriate criterion of eligibility to this treat-
ment is increased risk according to the international pro-
gnostic index. In these patients myeloablation with auto-
logous stem cell transplantation should be considered
as first choice treatment [57, 58, 59, 64]. An increasing
number of reports indicates that other immunological
and genetic characteristics of cells may have a signifi-
cant influence on therapeutic outcomes in patients with
the same level of risk [65]. Novel treatments include the
use of nonsense oligonucleotides and idiotypic vaccina-
tion [49]. Overexpression of bcl2 plays a major role in
malignant transformation leading to the development of
certain lymphomas and may decrease the efficacy of tre-
atment through inhibition of apoptosis [66]. If a non-
sense oligonucleotide fragment were bound with mRNA
fragment blocking the production of bcl2 protein on the
transcriptional level we could reverse drug refractori-
ness or even bring back normal apoptosis in cancer cells.
Preliminary results of studies using intravenous nonsen-
se oligonucleotide bcl2 are promising, confirming low
toxicity and good clinical efficacy [67]. In some lympho-
mas gene rearrangement sometimes results in overe-
xpression of the receptor, which is an immunoglobulin
molecule. A lymphoma-specific variable immunoglobulin
portion is referred to as an idiotype. Such immunoglobu-
lin administered to asymptomatic patients or those with
residual disease could induce an immune response and
antiimmunoglobulin production. The results of availa-
ble studies indicate that in patients with the immune re-
sponse symptom free survival is markedly improved [68].
Preliminary results of using new modalities are promi-
sing, thus increasing the possibilities of treating non-
-Hodgkin’s lymphomas in future.
Summing up, in each lymphoma apart from identify-
ing its morphological type it is important to submit a pa-
tient to a complete diagnostic process and to obtain the
information on the clinical characteristics that have an
adverse effect on prognosis. The identification of these
characteristics before the onset of treatment would al-
low us to adjust the intensity of treatment to the disease
aggressiveness, which increases with the presence of ad-
verse prognostic factors [34, 69, 70, 71]. At present the
best prognostic indicator both in low- and intermediate
grade lymphomas is the international prognostic index,
which is calculated based upon age (≤60 years vs. >60),
stage according to the Ann Arbor system (≤II vs. > II),
number of extranodal sites (≤1 vs. >1), performance sta-
tus (according to the WHO <2 vs. ≥2) and serum lactate
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dehydrogenase (normal vs. > normal). In patients with
low-grade lymphomas and IPI >1 it seems wise to consi-
der a more intensive treatment e.g. CHOP + Mabthera
regimen as first choice therapy [53, 55, 56]. Patients with
intermediate grade lymphomas should also be considered
as candidates for high-dose chemotherapy combined with
peripheral blood stem cell transplantation [59, 64, 71].
Conclusion
1. Improved prognosis in patients with non-Hodg-
kin’s lymphomas depends on exact staging of the dise-
ase, and especially obtaining a CT scan of the abdo-
men.
2. The international prognostic index is an important
prognostic factor both in low- and high grade lympho-
mas.
3. The presence of IPI score > 1 is associated with the
need for intensified treatment.
4. The achievement of complete remission significantly
affects overall survival in patients with low- and high-
-grade lymphomas.
5. Tumour bulk (> 10 cm in diameter), limited perfor-
mance (according to the WHO ≥2) and anaemia de-
crease the chances of remission in all types of non-
-Hodgkin’s lymphomas.
Edyta Jab∏oƒska M.D.
Oncology Clinic 
of the Jagiellonian University Medical College,
Kopernika 19, 31-501 Kraków
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